Celcuity Inc. Common Stock

Day range

$64.92 – $68.39

Open

$65.50

Prev close

$65.25

Volume

1.8M

Market cap

$3.19B

Shares out

48.93M

P/E

—

P/S

—

P/B

-249.81

P/FCF

—

ROE

1772.0%

ROA

-27.4%

Debt/Equity

-58.93

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentOct 2, 2026

  On October 1, 2026, the Board of Directors ... voted to increase the size of the Board from eight members to nine members and to appoint David W. Gryska as a new director to fill the resulting vacancy, effective immediately. ... The Board also appointed Mr. Gryska to serve as a member of the Audit Committee and Compensation Committee of the Board.

• Product or service launchSep 30, 2026

  On September 30, 2026, Celcuity Inc. (the "Company") issued a press release announcing that REVTORPYK™ (gedatolisib) is now commercially available in the United States for eligible patients with hormone receptor-positive ("HR+"), human epidermal growth factor receptor 2-negative ("HER2-"), locally advanced or metastatic breast cancer ("ABC") without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.

• Investor presentationJul 15, 2026

  The Company also plans to host a live webcast and conference call on July 14, 2026, at 4:30 p.m. CT to discuss the FDA approval of REVTORPYK. A copy of the presentation that will be provided during the live webcast is furnished as Exhibit 99.2 to this report.

• Underwriting agreementJun 8, 2026

  On June 3, 2026, Celcuity Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), agreeing, subject to customary conditions, to issue and sell in a public offering $500,000,000 aggregate principal amount of the Company's 0.250% Convertible Senior Notes due 2032.

• Regulatory decisionJun 2, 2026

  The FDA has granted Priority Review of Celcuity's New Drug Application ('NDA') for gedatolisib in patients with HR+/HER2- PIK3CA wild-type ('WT') ABC and assigned a Prescription Drug User Fee Act ('PDUFA') goal date of July 17, 2026.

Days to cover

11.0

Short interest

10.98M

Avg volume

995.7K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
  positiveGlobeNewswire Inc.· Oct 24, 2026
• New Strong Sell Stocks for October 14th
  negativeZacks Investment Research· Oct 14, 2026
• Why Celcuity Stock Was a Winner on Wednesday
  positiveThe Motley Fool· Sep 30, 2026
• NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Jul 29, 2026
• CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Jul 21, 2026